Hatchtech

All Categories

02 August 2020

FDA Approves Xeglyze™ for the topical treatment of head lice infestation

02 August 2020

Hatchtech gets lice treatment nod from FDA

News, The Australian Financial Review

01 February 2018

No nit picking: Head lice group Hatchtech gets green light to trials

News, The Australian Financial Review

14 September 2015

Hatchtech inks $279m head lice deal as VC market comes to life

Sydney Morning Herald

26 March 2015

Hatchtech Pty Ltd to explore strategic alternatives for commercialization of Xeglyze™ lotion in the U.S.

21 October 2014

Hatchtech announces successful results from Phase 2 ovicidal study

27 January 2014

Australia’s Hatchtech ‘itching’ to partner at J.P. Morgan

01 November 2013

Hatchtech gets new VC backing for lice treatment trial

01 November 2013

Hatchtech hardly a head-scratcher for investors

01 November 2013

Lice feel the itch over Hatchtech deal

31 October 2013

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

12 March 2013

Hugh Alsop appointed Hatchtech CEO

27 November 2012

Hatchtech publish data on Head Lice treatment safety study and mechanism of action

25 October 2012

Novel Pediculicide Clears Most Head Lice With 1 Application

03 September 2012

Hatchtech announce successful End-of-Phase 2 for head lice product DeOvo™

26 October 2010

Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial

21 June 2006

Hatchtech wins prize for best Victorian technology commercialisation from all industries

21 June 2006

Hatchtech wins Commercialisation Expo 2006 Prize for Best Australian Life Sciences Company

decor decor decor
decor decor decor decor decor